Natural history of surgically treated high-risk prostate cancer

Briganti, Alberto; Karnes, R. Jeffrey; Gandaglia, Giorgio; Spahn, Martin; Gontero, Paolo; Tosco, Lorenzo; Kneitz, Burkhard; Chun, Felix K.‐H.; Zaffuto, Emanuele; Sun, Maxine; Graefen, Markus; Marchioro, G.; Frohneberg, D.; Giona, Simone; Karakiewicz, Pierre I.; Poppel, Hein Van; Montorsi, Francesco; Joniau, Steven

doi:10.1016/j.urolonc.2014.11.018

Cited by 109 publications

(76 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, in our cohort, the 10-year BCR-free rate was 50%. This rate is again comparable with those reported for highrisk PCa patients treated with ORP (10-yr BCR-free survival rate ranging from 35% to 59%, based on tumor characteristics) [24,31], and it is superior to those reported for patients treated with external-beam radiation therapy with or without HT [32]. Ritch et al [33], in their contemporary study comparing ORP and RARP in patients with intermediate-to high-risk PCa, also observed that, after adjusting for confounders, RARP and ORP had equitable odds for BCR.…”

Section: Discussionsupporting

confidence: 86%

Long-term Cancer Control Outcomes in Patients with Clinically High-risk Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Results from a Multi-institutional Study of 1100 Patients

et al. 2015

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 86%

Long-term Cancer Control Outcomes in Patients with Clinically High-risk Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Results from a Multi-institutional Study of 1100 Patients

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…Although primary treatment of clinically localized PCa is associated with excellent oncological results, up to half the patients treated with radical prostatectomy (RP) or external beam radiotherapy (EBRT) experience biochemical recurrence (BCR) during follow-up [3][4][5][6][7]. Several tools evaluating numerous clinical and pathological parameters such as prostate-specific antigen (PSA) kinetics (such as doubling time and velocity), pathological Gleason score (GS), pathological T and N stage are now available and used by physicians to assess the probability of harbouring local or systemic recurrence after RP or EBRT [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series

Graziani

Ceci

Castellucci

et al. 2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…High-risk prostate cancer is localized by definition and thus potentially curable, but cure rates are only 50% to 60%. Of the patients who experience recurrence, 30% to 40% progress to metastatic disease that ultimately leads to death (4,5). Therefore, there is a critical need to identify which patients are at greatest risk for metastatic progression, and to identify biologic drivers that can be targeted to improve outcomes for these patients (1).…”

Section: Introductionmentioning

confidence: 99%

The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer

Zhao

Evans

Kothari

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: There is a clear need to improve risk stratification and to identify novel therapeutic targets in aggressive prostate cancer. The goal of this study was to investigate genes with outlier expression with prognostic association in high-risk prostate cancer patients as potential biomarkers and drug targets.Experimental Design: We interrogated microarray gene expression data from prostatectomy samples from 545 high-risk prostate cancer patients with long-term follow-up (mean 13.4 years). Three independent clinical datasets totaling an additional 545 patients were used for validation. Novel prognostic outlier genes were interrogated for impact on oncogenic phenotypes in vitro using siRNA-based knockdown. Association with clinical outcomes and comparison with existing prognostic instruments was assessed with multivariable models using a prognostic outlier score.Results: Analysis of the discovery cohort identified 20 prognostic outlier genes. Three top prognostic outlier genes were novel prostate cancer genes; NVL, SMC4, or SQLE knockdown reduced migration and/or invasion and outlier expression was significantly associated with poor prognosis. Increased prognostic outlier score was significantly associated with poor prognosis independent of standard clinicopathologic variables. Finally, the prognostic outlier score prognostic association is independent of, and adds to existing genomic and clinical tools for prognostication in prostate cancer (Decipher, the cell-cycle progression signature, and CAPRA-S).Conclusions: To our knowledge, this study represents the first unbiased high-throughput investigation of prognostic outlier genes in prostate cancer and demonstrates the potential biomarker and therapeutic importance of this previously unstudied class of cancer genes.

show abstract

Natural history of surgically treated high-risk prostate cancer

Cited by 109 publications

References 30 publications

Long-term Cancer Control Outcomes in Patients with Clinically High-risk Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Results from a Multi-institutional Study of 1100 Patients

Long-term Cancer Control Outcomes in Patients with Clinically High-risk Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Results from a Multi-institutional Study of 1100 Patients

11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series

The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer

Contact Info

Product

Resources

About